Aaron T Schatzmann, Tania A Stallons, Rachel Rivera, Quy P Nguyen, Rémy Dureau, Julien J Torgue
{"title":"Microbial Cytotoxic Effect of <sup>212</sup>Pb in Radiopharmaceuticals.","authors":"Aaron T Schatzmann, Tania A Stallons, Rachel Rivera, Quy P Nguyen, Rémy Dureau, Julien J Torgue","doi":"10.1089/cbr.2024.0208","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Background:</i></b> The cytotoxic effect of <sup>212</sup>Pb on microbial growth was examined, using six microorganisms, at clinically relevant time points, to determine the potency of <sup>212</sup>Pb as a self-sterilizing agent in radiopharmaceuticals using [<sup>212</sup>Pb]Pb-DOTAMTATE. <b><i>Materials and Methods:</i></b> Vials of radiolabeled [<sup>212</sup>Pb]Pb-DOTAMTATE, nonradiolabeled DOTAMTATE, and appropriate media were inoculated with <i>Bacillus spizizenii</i>, <i>Candida albicans, Clostridium sporogenes, Pseudomonas aeruginosa, Staphylococcus aureus,</i> or <i>Aspergillus brasiliensis</i>. Samples from each vial type were plated onto tryptic soy agar or Sabouraud dextrose plates and allowed to grow at optimal temperature for each strain to obtain quantifiable colony forming units (CFU). <b><i>Results:</i></b> Each microbial organism observed at least a 6 log reduction in total CFUs after 6 h of exposure to [<sup>212</sup>Pb]Pb-DOTAMTATE drug product vials, showing no remaining colonies as compared to the vials containing only media and drug formulation with no radiolabeled material, utilizing a low absorbed dose of no greater than 1.01 kGy. A sterility assessment of the two [<sup>212</sup>Pb]Pb-DOTAMTATE drug product vials containing the lowest total CFUs per vial displayed no microbial growth upon incubation for 14 d. <b><i>Conclusions:</i></b> This study suggests that <sup>212</sup>Pb in radiopharmaceuticals is a potent microbial cytotoxic agent with self-sterilizing properties.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biotherapy and Radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/cbr.2024.0208","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Microbial Cytotoxic Effect of 212Pb in Radiopharmaceuticals.
Background: The cytotoxic effect of 212Pb on microbial growth was examined, using six microorganisms, at clinically relevant time points, to determine the potency of 212Pb as a self-sterilizing agent in radiopharmaceuticals using [212Pb]Pb-DOTAMTATE. Materials and Methods: Vials of radiolabeled [212Pb]Pb-DOTAMTATE, nonradiolabeled DOTAMTATE, and appropriate media were inoculated with Bacillus spizizenii, Candida albicans, Clostridium sporogenes, Pseudomonas aeruginosa, Staphylococcus aureus, or Aspergillus brasiliensis. Samples from each vial type were plated onto tryptic soy agar or Sabouraud dextrose plates and allowed to grow at optimal temperature for each strain to obtain quantifiable colony forming units (CFU). Results: Each microbial organism observed at least a 6 log reduction in total CFUs after 6 h of exposure to [212Pb]Pb-DOTAMTATE drug product vials, showing no remaining colonies as compared to the vials containing only media and drug formulation with no radiolabeled material, utilizing a low absorbed dose of no greater than 1.01 kGy. A sterility assessment of the two [212Pb]Pb-DOTAMTATE drug product vials containing the lowest total CFUs per vial displayed no microbial growth upon incubation for 14 d. Conclusions: This study suggests that 212Pb in radiopharmaceuticals is a potent microbial cytotoxic agent with self-sterilizing properties.
期刊介绍:
Cancer Biotherapy and Radiopharmaceuticals is the established peer-reviewed journal, with over 25 years of cutting-edge content on innovative therapeutic investigations to ultimately improve cancer management. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies.
The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments.